checkAd

    EQS-News  142  0 Kommentare Mainz Biomed Strengthens Board of Directors with Nomination of Dr. Heiner Dreismann and Gregory Tibbitts - Seite 2

     

    Mr. Gregory Tibbitts is a Certified Public Accountant with over 30 years of professional experience as a senior financial executive and as a board member of publicly traded and privately held companies. His expertise includes multiple debt and equity transactions, restructure of complex manufacturing operations, resolution of technical accounting issues and direct interactions with the United States Securities and Exchange Commission. He worked as a Chief Financial Officer for both public and private companies, primarily in the medical diagnostics and life sciences sectors. He currently serves as a board member for CoImmune Inc, a biotechnology company and served as a board member for IDMI Pharma, Inc., a NASDAQ listed biotech company prior to its acquisition. He obtained a B.B.A. at University of San Diego and an M.B.A. at San Diego State University. Mr. Tibbitts does not currently hold ordinary shares of the Company.

     

    Mainz Biomed NV intends to hold an extraordinary general meeting the week of December 12, 2022. The official announcement, notice of meeting, agenda for the meeting and related documents and further information regarding the meeting will be made available on the Company's website at https://www.mainzbiomed.com/investors in early October 2022.

    During the meeting, shareholders will be asked to vote on the appointment of up to two additional non-executive directors.

     

    If appointed, each of Dr. Dreismann and Mr. Tibbitts would be non-executive directors. Non-executive directors are appointed at the annual extraordinary meeting on the basis of one or more binding nominations made by the Board of Directors or by one or more shareholders who individually or jointly represent at least twenty percent of the issued share capital of the Company. At the date hereof, the issued share capital of the Company consists of 14,482,973 ordinary shares with a nominal value of EUR 0.01 each.

     

    Each nomination may comprise one candidate only. To be valid, a nomination shall specify the vacancy for which the nomination is made, the candidate's age and profession, the number of shares in the share capital of the Company held by him or her and the positions he or she holds or held insofar as relevant to the fulfillment of the duties as a non-executive director of the Company. Furthermore, mention shall be made of the legal persons for which he or she serves as a director whereby, provided that if legal persons are included which belong to the same group, it shall be sufficient to mention such group. The nomination for appointment shall include the reasons therefor.

    Seite 2 von 5



    EQS Group AG
    0 Follower
    Autor folgen

    Weitere Artikel des Autors

    Verfasst von EQS Group AG
    EQS-News Mainz Biomed Strengthens Board of Directors with Nomination of Dr. Heiner Dreismann and Gregory Tibbitts - Seite 2 Issuer: Mainz BioMed N.V. / Key word(s): Personnel Mainz Biomed Strengthens Board of Directors with Nomination of Dr. Heiner Dreismann and Gregory Tibbitts 28.09.2022 / 14:10 CET/CEST The issuer is solely responsible for the content of this …